Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Ovarian, Fallopian Tube, or Peritoneal Cancer in Second or Greater Remission
NCT00522301Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00522301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522301.